CN Patent

CN114163309B — 一种多拉韦林中间体的制备方法

Assigned to Gansu Haotian Pharma Tech Co ltd · Expires 2023-04-25 · 3y expired

What this patent protects

本发明公开了一种多拉韦林中间体的制备方法。该方法以4‑氨基‑3‑氯苯酚为起始原料，经碘代、重氮化并经原位还原、精制得到目标化合物(Ⅰ)。该方法所用原辅材料及试剂毒性小，安全而且价廉易得，所用试剂都为常规试剂，能够有效降低成本；工艺过程简单，操作方便，条件温和，极大地降低了生产上对于设备的要求；最终制得的产品收率高、质量好，可以实现规模化生产。

USPTO Abstract

本发明公开了一种多拉韦林中间体的制备方法。该方法以4‑氨基‑3‑氯苯酚为起始原料，经碘代、重氮化并经原位还原、精制得到目标化合物(Ⅰ)。该方法所用原辅材料及试剂毒性小，安全而且价廉易得，所用试剂都为常规试剂，能够有效降低成本；工艺过程简单，操作方便，条件温和，极大地降低了生产上对于设备的要求；最终制得的产品收率高、质量好，可以实现规模化生产。

Drugs covered by this patent

Patent Metadata

Patent number
CN114163309B
Jurisdiction
CN
Classification
—
Expires
2023-04-25
Drug substance claim
No
Drug product claim
No
Assignee
Gansu Haotian Pharma Tech Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.